DDInter1570 DDInter817
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Guaifenesin {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Acetophenazine
Acetophenazine {u} (Compound) resembles {v} (Compound) Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) resembles Guaifenesin (Compound) and Guaifenesin (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Gilteritinib
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Gilteritinib
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib